The world's good news, every day.

RSS
Just Positive

Section

Health

Medicine, public health, and care that is reaching more people — breakthroughs with names and faces attached.

11 stories

Scanning electron micrograph of a single human T lymphocyte, or T cell, from the immune system of a healthy donor, its surface covered in small projections. Illustrative image of a T cell, not from the invika trial. Image: NIAID/NIH, public domain, via Wikimedia Commons. Source page: https://commons.wikimedia.org/wiki/File:Healthy_Human_T_Cell.jpg

Health

An Experimental Precision T-Cell Drug Held Off Treatment-Resistant Cancers in an Early Trial, NIH Reports

In an early phase 1/2 trial led by researchers at the National Institutes of Health, Mass General Brigham and Memorial Sloan Kettering, an experimental drug called invika kept cancer from progressing in 16 of 27 patients treated at its optimal dose, most of whom had tumors that resisted standard immunotherapy. Four saw their tumors shrink by more than 30 percent. The drug is not approved, and the trial is continuing.

Just News Desk · 26 October 2026

Main entrance of Building 1 on the U.S. Food and Drug Administration's White Oak campus, Silver Spring, Maryland, 12 March 2015. Photo: U.S. Food and Drug Administration, via Wikimedia Commons (public domain, U.S. government work). Source page: https://commons.wikimedia.org/wiki/File:FDA_Entrance_(16792957331).jpg

Health

FDA Opens a Public Review of How It Judges Rare Disease Treatments, Seeking a Framework Built for Small Patient Populations

The U.S. Food and Drug Administration announced on 14 October a Rare Disease Framework Initiative to develop a fit-for-purpose approach to reviewing drugs and biologics for rare diseases, and will seek public input at a hybrid meeting on its White Oak campus on 28 October. The effort is a policy consultation; it approves no new treatments.

Just News Desk · 19 October 2026

The main entrance of FDA Building 1 on the White Oak campus in Silver Spring, Maryland, which houses the commissioner's and senior staff offices. Photo: U.S. Food and Drug Administration, via Wikimedia Commons (public domain). Source page: https://commons.wikimedia.org/wiki/File:FDA_Bldg_1_-_Exterior_With_Circle_(5161374950).jpg

Health

FDA Approves a Tucatinib Maintenance Regimen for Advanced HER2-Positive Breast Cancer

On 7 October 2026 the FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy for adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction treatment, based on longer progression-free survival in the HER2CLIMB-05 trial. Overall survival data were not yet mature, and the label carries warnings that include diarrhea and hepatotoxicity.

Just News Desk · 14 October 2026

The morning briefing

A handful of hopeful stories, once a week.

No doomscroll. No ads sold against your attention. Just the week’s brightest, most carefully reported pieces — in one letter.